Matthew T. DeSilva

matthew.desilva@lw.com

+1.212.906.4563

Profile

Matthew T. DeSilva, an associate in the Capital Markets Practice, represents financial institutions, private equity firms, and issuer clients in a variety of complex capital markets and corporate finance transactions.

Mr. DeSilva works on matters across various industries and regions. His transaction work includes advising on:

Initial public offerings (IPOs) and subsequent equity financings
Preferred equity and holdco PIK financings
Acquisition financings and exchange offers
High-yield and investment grade debt offerings
SEC related matters, corporate governance, and other general corporate matters

Mr. DeSilva was previously seconded to Barclays, where he advised on a broad array of equity, equity-linked, and debt capital markets transactions.

Prior to joining Latham full-time, Mr. DeSilva was a summer associate in the New York office. While attending law school at Boston College, Mr. DeSilva served as a senior editor for the Boston College Law Review and graduated cum laude. Mr. DeSilva served as a legal intern in the Division of Enforcement at the United States Securities and Exchange Commission during his second year of law school and at the New York State Office of the Attorney General in the summer following his first year.

Experience

DeSilva’s experience includes advising:

Private Capital and Acquisition Finance

Investors on a US$500 million preferred equity investment as part of a larger financing for the Zendesk leveraged buyout
Investors on the third-party minority equity investment and holdco PIK note for the Virgin Pulse and HealthComp merger
Blackstone, The Carlyle Group, HPS Investment Partners, Odyssey Investment Partners, Neuberger Berman and other top-tier sponsors on private capital investments
VillageMD on its US$8.9 billion acquisition of Summit Health-CityMD

IPOs, Subsequent Equity, Equity Derivative and Other Equity Financings

Duolingo in its US$598 million IPO
Casper Sleep in its US $100 million IPO
Zentalis Pharmaceuticals in its US$190 million IPO and subsequent follow-on offerings, registered direct offering, at-the-market offerings and US$25 million equity investment from Pfizer
VillageMD in its US$5.2 billion investment from Walgreens Boots Alliance
fuboTV Inc. in its exchange of US$205 million existing convertible senior notes for US$177 million new convertible senior secured notes
Inspire Medical Systems in its US$108 million IPO and follow-on offering
The underwriters on:
- Birkenstock's US$1.5 billion IPO
- American Well's US$853 million IPO and subsequent secondary offerings
- Similarweb’s US$176 million IPO
- Vor Biopharma’s US$203 million IPO and subsequent US$115 million concurrent follow on offering and PIPE transaction
- Landos Biopharma's US$100 million IPO
- Rocket Pharmaceuticals US$175 million common stock offering
- Acumen Pharmaceuticals US$130 million common stock offering
- Freshpet’s US$345 million secondary offering of common stock
- Alphatec Holdings US$115 million secondary offering of common stock

High Yield and Investment Grade Debt

Amgen in its US$24.0 billion offering of senior notes (as of the date of issuance, the ninth largest corporate debt issuance and second largest healthcare corporate debt issuance in history, according to Dealogic) to fund its acquisition of Horizon Therapeutics, $4.0 billion offering of senior notes (which included Amgen’s inaugural offering of green bonds) and $3.0 billion offering of senior notes
Boyd Gaming in its US$900 million offering of senior
Sempra Energy in its US$1.25 billion offering of senior notes
The initial purchasers on:
- Mohegan Tribal Gaming Authority’s US$1.2 billion offering of senior secured notes
- Danaher’s US$1.0 billion, €6.25 billion and US$4.0 billion offerings of registered senior notes
- SoFi Technologies US$1.1 billion convertible senior notes offering